IN VITRO RELEASE STUDIES OF CARBAMAZEPINE TABLETS AND BENZOYL METRONIDAZOLE SUSPENSIONS USING THE FLOW-THROUGH CELL APPARATUS AND SIMULATED GASTROINTESTINAL FLUIDS
Objective: To characterize the in vitro release of carbamazepine tablets and benzoyl metronidazole suspensions using the flow-through cell apparatus and simulated gastrointestinal fluids.
Methods: TegretolÂ® tablets, FlagylÂ® suspension, and generic formulations of each were tested. Release studies were performed using an automated flow-through cell apparatus. Simulated gastric fluid (with and without pepsin) and simulated intestinal fluid (without pancreatin) at 16 ml/min and fasted state simulated intestinal fluid at 8 ml/min, all at 37.0Â±0.5 Â°C, were used as dissolution media. The quantity of dissolved carbamazepine and benzoyl metronidazole was determined at 5-min intervals until 60 min at 285 and 278 nm, respectively. Percentage dissolved at 60 min, mean dissolution time, dissolution efficiency values, and t10%, t25%, t50% and t63.2% were calculated. Mean values for all parameters were compared between the reference and generic formulations using StudentÊ¼s t-test. Dissolution data were fitted to different kinetic models.
Results: Simulated gastric fluid without pepsin showed no discriminative capability for carbamazepine tablets. Significant differences were observed between the reference and generic formulations for almost all parameters (*P<0.05). In some cases, the logistic model best described the in vitro release of both drugs.Conclusion: Using an apparatus and media that best simulates the gastrointestinal environment, we identified differences in the rate and extent of dissolution of both drugs that could help to optimise the design of interchangeable formulations. Based on the physicochemical characteristics of carbamazepine and benzoyl metronidazole and the conditions in which the formulations were tested, these differences could be of clinical relevance.
2. Santos Da Silva A, Da Rosa Silva CE, FÃ¡vero P, Barcellos FE. Discriminative dissolution method for benzoyl metronidazole oral suspension. AAPS PharmSciTech 2015;17:778âˆ’86.
3. Namdev N. Formulation and evaluation of egg albumin-based controlled release microspheres of metronidazole. Int J Curr Pharm Res 2016;8:28âˆ’32.
4. Lindenberg M, Kopp S, Dressman JB. Classification of orally administered drugs on the World Health Organization model list of essential medicines according to the biopharmaceutics classification system. Eur J Pharm Biopharm 2004;58:265âˆ’78.
5. Kasim NA, Whitehouse M, Ramachandran C, Bermejo M, LennernÃ¤s H, Hussain AS, et al. Molecular properties of the WHO essential drugs and provisional biopharmaceutical classification. Mol Pharm 2004;1:85â€“96.
6. Dahan A, Miller JM, Amidon GL. Prediction of solubility and permeability class membership: provisional BCS classification of the worldâ€™s top oral drugs. AAPS J 2009;11:740â€“6.
7. Therapeutic System Research Laboratories TSRL inc. Biopharmaceutics Classification System (BCS) Results. Available from: http://www.tsrlinc.net/search.cfm [Last accessed on 01 Apr 2017]
8. Kumar L, Deshpande A, Page A. Super generics/improved therapeutic entities: an approach to fulfil unmet medical needs and extending market exclusivity of generic medicines. Int J Pharm Pharm Sci 2015;7:25âˆ’9.
9. United States Pharmacopeia and National Formulary USP 40-NF 35; The United States Pharmacopeial Convention, Inc: Rockville MD; 2017.
10. Zoeller T, Klein S. Simplified biorelevant media for screening dissolution performance of poorly soluble drugs. Dissolution Technol 2007;14:8âˆ’13.
11. Wang Q, Fotaki N, Mao Y. Biorelevant dissolution: methodology and application in drug development. Dissolution Technol 2009;16:6-12.
12. Marques MRC, Loebenberg R, Almukainzi M. Simulated biological fluids with possible application in dissolution testing. Dissolution Technol 2011;18:15âˆ’28.
13. Kloefer B, van Hoogevest P. Technical note: using biorelevant media with different types of orally administered formulations. Dissolution Technol 2010;17:46âˆ’7.
14. Marques M. Dissolution media simulating fasted and fed states. Dissolution Technol 2004;11:16.
15. CÃ¡rdenas HL, CortÃ©s AR, Argotte R, Luna P, DomÃnguez A. Investigation of dissolution profiles from suspensions containing benzoyl metronidazole using a statistical model with repeated measurements. Drug Dev Ind Pharm 1994;20:1063âˆ’73.
16. Zietsman S, Kilian G, Worthington M, Stubbs C. Formulation development and stability studies of aqueous metronidazole benzoate suspensions containing various suspending agents. Drug Dev Ind Pharm 2007;33:191âˆ’7.
17. Singh I, Aboul-Enein HY. Advantages of USP apparatus IV (flow-through cell apparatus) in dissolution studies. J Iran Chem Soc 2006;3:220â€“2.
18. Qui S, Wang K, Li M. In vitro dissolution studies of immediate-release and extended release formulations using flow-through cell apparatus 4. Dissolution Technol 2014;21:6âˆ’15.
19. Sunesen VH, Pedersen BL, Kristensen HG, MÃ¼llertz A. In vivo in vitro correlations for a poorly soluble drug, danazol, using the flow-through dissolution method with bio-relevant dissolution media. Eur J Pharm Sci 2005;24:305â€“13.
20. Szymanska E, Winnicka K. Comparison of the flow-through cell and paddle methods for testing vaginal tablets containing a poorly water-soluble drug. Trop J Pharm Res 2013;12:39â€“44.
21. Emara LH, Emam MF, Taha NF, El-Ashmawy AA, Mursi NM. In vitro dissolution study of meloxicam immediate release products using flow-through cell (USP apparatus 4) under different operational conditions. Int J Pharm Pharm Sci 2014;6:254âˆ’60.
22. Fotaki N, Reppas C. The flow through cell methodology in the evaluation of intralumenal drug release characteristics. Dissolution Technol 2005;12:17âˆ’21.
23. Nicolaides E, Hempenstall JM, Reppas C. Biorelevant dissolution tests with the flow-through apparatus? Dissolution Technol 2000;7:1âˆ’4.
24. Jantratid E, De Maio V, Ronda E, Mattavelli V, Vertzoni M, Dressman JB. Application of biorelevant dissolution tests to the prediction of in vivo performance of diclofenac sodium from an oral modified-release pellet dosage form. Eur J Pharm Sci 2009;37:434âˆ’41.
25. Listado de Medicamentos de Referencia. Cofepris. Mexico. Available from: http://codigof.mx/medicamentos-de-referencia-actualizacion- y-lineamientos. [Last accessed on 21 Mar 2017]
26. Galia E, Nicolaides E, HÃ¶rter D, LÃ¶benberg R, Reppas C, Dressman JB. Evaluation of various dissolution media for predicting in vivo performance of Class I and II drugs. Pharm Res 1998;15:698âˆ’705.
27. Zhang Y, Huo M, Zhou J, Zou A, Li W, Yao C, et al. DD solver: an add-in program for modeling and comparison of drug dissolution profiles. AAPS J 2010;12:263âˆ’71.
28. Yuksel N, Kanik AE, Baykara T. Comparison of in vitro dissolution profiles by ANOVA-based, model-dependent and independent methods. Int J Pharm 2000;209:57âˆ’67.
29. Olling M, Mensinga TT, Barends DM, Groen C, Lake OA, Meulenbelt J. Bioavailability of carbamazepine from four different products and the occurrence of side effects. Biopharm Drug Dispos 1999;20:19âˆ’28.
30. Rentmeester TW, Doelman JC, Hulsman JA. Carbamazepine: branded formulation versus generic formulation. Pharmaceutish Weekbland 1990;125:1108âˆ’10.
31. Medina JR, Salazar DK, Hurtado M, CortÃ©s AR, DomÃnguez-RamÃrez AM. Comparative in vitro dissolution study of carbamazepine immediate-release products using the USP paddles method and the flow-through cell system. Saudi Pharm J 2014;22:141âˆ’7.
32. Girard ME, MillÃ¡n R, Jung H, Torres S, Montoya MA. Dissolution study of carbamazepine tablets. Rev Mex Cienc Farm 1996;27:13âˆ’7.
33. Rediguieri CF, Porta V, Nunes DSG, Nunes TM, Junginger HE, Kopp S, et al. Biowaiver monographs for immediate release solid oral dosage forms: metronidazole. J Pharm Sci 2011;100:1618âˆ’27.
34. Medina JR, Ortiz HD, Hurtado M, DomÃnguez-RamÃrez AM. Influence of dose and the USP basket and flow-through cell dissolution apparatus in the release kinetics of metronidazole immediate-release products. Int J Res Pharm Sci 2014;5:137âˆ’46.
35. Langenbucher F, Benz D, Kurth W, Moller H, Otz M. Standardized flow-cell method as an alternative to existing pharmacopoeial dissolution testing. Pharm Ind 1989;51:1276âˆ’81.
36. Steffansen B, Brodin B, Und Nielsen C. editors. Molecular Biopharmaceutics. ULLA Pharmacy Series. Pharmaceutical Press; 2010.
37. Fotaki N, Symillides M, Reppas C. In vitro versus canine data for predicting input profiles of isosorbide-5-mononitrate from oral extended release products on a confidence interval basis. Eur J Pharm Sci 2005;24:115âˆ’22.
38. Bhise SB, Rajkumar. Influence of simulated gastrointestinal fluids on polymorphic behavior of anhydrous carbamazepine form III and biopharmaceutical relevance. PDA J Pharm Sci Technol 2010;64:28âˆ’36.
39. DemirtÃ¼rk E, Ã–ner L. In vitro-in vivo correlations. FABAD J Pharm Sci 2003;28:215âˆ’24.
40. Anderson NH, Bauer M, Boussac N, Khan-Malek R, Munden P, Sardaro M. An evaluation of fit factors and dissolution efficiency for the comparison of in vitro dissolution profiles. J Pharm Biomed Anal 1998;17:811âˆ’22.
41. Costa P, Sousa Lobo JM. Modelling and comparison of dissolution profiles. Eur J Pharm Sci 2001;13:123âˆ’33.